DUBLIN--(BUSINESS WIRE)--The "Investigation Report on Chinese Thymosin a1 Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering. According to the report, Thymosin 1 has been ...
Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: A phase Ib/IIa clinical study. This is an ASCO Meeting ...
Thymosin Alpha 1 (Tα1) is a naturally occurring 28‐amino acid peptide renowned for its capacity to modulate immune responses. Extensive research has delineated its ability to enhance T-cell activation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback